Completed EARLY_PHASE1 INTERVENTIONAL 1-arm NCT04321161

Analysis of T Cell Metabolism in Relapsed AML Patients With DLIs and Bicanorm Treatment

Analysis of T Cell Metabolism and Immune Phenotype in Relapsed Acute Myeloid Leukemia Patients Receiving Donor Lymphocyte Infusions and Bicanorm (Sodium Bicarbonate)

Sponsor: University of Freiburg

Conditions Acute Myeloid Leukemia, in Relapse

Interventions Bicanorm

Updated 5 times since 2020 Last updated: Mar 24, 2020 Started: Feb 25, 2020 Primary completion: Mar 18, 2020 Completion: Mar 18, 2020

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This EARLY_PHASE1 trial investigates Acute Myeloid Leukemia, in Relapse and is currently completed. University of Freiburg leads this study, which shows 5 recorded versions since 2020 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

5 versions recorded

Sep 2025 — Present [monthly]

Completed EARLY_PHASE1
Sep 2024 — Sep 2025 [monthly]

Completed EARLY_PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed EARLY_PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed EARLY_PHASE1
Apr 2020 — Jan 2021 [monthly]

Completed EARLY_PHASE1

First recorded

Feb 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University of Freiburg

Data source: University of Freiburg

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Freiburg im Breisgau, Germany